文献速递脑血管病

基底动脉闭塞血管内治疗前替奈普酶与阿替普酶比较

Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion.
PubMed 文献 · Neurology · 2021-01-06

本研究回顾性分析BATMAN注册研究和EXTEND-IA TNK试验中110例基底动脉闭塞患者,比较血管内治疗前静脉替奈普酶(TNK)与阿替普酶的效果。结果显示TNK组初始造影再灌注>50%或无可取出血栓的比例为26%(5/19),阿替普酶组为7%(6/91),风险比4.0(95%CI 1.3-12;p=0.02),症状性颅内出血无差异(0/19 vs 1/91;p=0.9)。结论提示TNK可能与更高的再灌注率相关,需随机对照试验验证。

要点

  • 基底动脉闭塞血管内治疗前,TNK组再灌注率26%高于阿替普酶组7%。
  • TNK组症状性颅内出血0/19,阿替普酶组1/91,无统计学差异。
  • 该研究为Class III证据,支持TNK可能提高再灌注率,需RCT证实。

核心结论

  • 在基底动脉闭塞患者中,血管内治疗前使用替奈普酶可能较阿替普酶提高再灌注率。

研究设计与样本

  • 回顾性分析BATMAN注册研究和EXTEND-IA TNK试验中110例基底动脉闭塞患者,均接受血管内治疗前静脉溶栓。
  • TNK组19例(0.25 mg/kg或0.40 mg/kg),阿替普酶组91例(0.9 mg/kg)。

主要发现

  • 初始造影再灌注>50%或无可见可取出血栓:TNK组26%(5/19),阿替普酶组7%(6/91),风险比4.0(95%CI 1.3-12;p=0.02)。
  • 症状性颅内出血:TNK组0/19(0%),阿替普酶组1/91(1%),p=0.9。
  • TNK组溶栓至动脉穿刺时间48分钟(IQR 40-71),短于阿替普酶组的110分钟(IQR 51-185),p=0.004。

关键数值与推荐

  • 再灌注评估标准为初始造影再灌注>50%或无可取出血栓。
  • TNK剂量为0.25 mg/kg或0.40 mg/kg,阿替普酶剂量为0.9 mg/kg。

临床怎么用

  • 对于拟行血管内治疗的基底动脉闭塞患者,可考虑优先使用替奈普酶而非阿替普酶以提高早期再灌注可能。
  • 需注意本研究为回顾性分析,证据等级为Class III,临床决策应结合个体情况并等待随机对照试验结果。

局限性

  • 回顾性研究设计,样本量较小(TNK组仅19例)。
  • TNK组溶栓至穿刺时间显著短于阿替普酶组,可能存在混杂偏倚。
  • 证据等级为Class III,结论需前瞻性随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy of tenecteplase (TNK), a genetically modified variant of alteplase with greater fibrin specificity and longer half-life than alteplase, prior to endovascular thrombectomy (EVT) in patients with basilar artery occlusion (BAO). METHODS: To determine whether TNK is associated with better reperfusion rates than alteplase prior to EVT in BAO, clinical and procedural data of consecutive patients with BAO from the Basilar Artery Treatment and Management (BATMAN) registry and the Tenecteplase vs Alteplase before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) trial were retrospectively analyzed. Reperfusion >50% or absence of retrievable thrombus at the time of the initial angiogram was evaluated. RESULTS: We included 110 patients with BAO treated with IV thrombolysis prior to EVT (mean age 69 [SD 14] years; median NIH Stroke Scale score 16 [interquartile range (IQR) 7-32]). Nineteen patients were thrombolysed with TNK (0.25 mg/kg or 0.40 mg/kg) and 91 with alteplase (0.9 mg/kg). Reperfusion >50% occurred in 26% (n = 5/19) of patients thrombolysed with TNK vs 7% (n = 6/91) thrombolysed with alteplase (risk ratio 4.0, 95% confidence interval 1.3-12; p = 0.02), despite shorter thrombolysis to arterial puncture time in the TNK-treated patients (48 [IQR 40-71] minutes) vs alteplase-treated patients (110 [IQR 51-185] minutes; p = 0.004). No difference in symptomatic intracranial hemorrhage was observed (0/19 [0%] TNK, 1/91 [1%] alteplase; p = 0.9). CONCLUSIONS: TNK may be associated with an increased rate of reperfusion in comparison with alteplase before EVT in BAO. Randomized controlled trials to compare TNK with alteplase in patients with BAO are warranted. CLINICALTRIALSGOV IDENTIFIERS: NCT02388061 and NCT03340493. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that TNK leads to higher reperfusion rates in comparison with alteplase prior to EVT in patients with BAO.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Alemseged F, Ng FC, Williams C, et al. Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion. Neurology. 2021. PMID: 33408145. doi:10.1212/WNL.0000000000011520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。